Testing a depression medication plan using symptom predictions
Treatments studied
Part of Mental health clinical trials.
This Phase 4 study tests an “optimized” medication approach for adults with major depressive disorder (unipolar depression) based on how you respond over time. It may help your care team choose treatments more effectively and reduce trial-and-error.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an outpatient age 18 to 65
- Have current major depression (diagnosed by a structured interview)
- Be currently off most mood/psychiatric medicines for long enough before starting the study (except certain stable sleep or ADHD medicines)
- Score high enough on a depression symptom scale (MADRS 24 or higher)
- Be able to read and speak English well enough for interviews and questionnaires
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses computer modeling based on brain measurements to try to predict which depression treatment will work for you. It may help match you with the most effective option faster by understanding your motivation-related brain patterns.
This trial tests a personalized approach to treating major depressive disorder using assessments and brain imaging to match you with the best therapy. It aims to improve outcomes by tailoring care to your specific needs.
This study tests a new way of choosing antidepressants for people with major depression. It's designed for adults aged 19–65 who have moderate to severe depression and are either starting a new antidepressant or have been off psychiatric meds for at least a month.
This trial studies whether a personalized combination of talk therapy (CBT) and antidepressant medication works better for people with moderate to severe depression. It’s meant to match treatment choices to your situation and to see what helps most.
This study tests an experimental oral pill called azetukalner against a placebo to see if it safely reduces symptoms of major depressive disorder. It is for adults who are currently in a depressive episode lasting 6 weeks to 2 years and have not already tried multiple antidepressants that failed.
This Phase 3 study tests a stronger medication approach after your first current treatment hasn’t worked well enough. It targets people with schizophrenia, major depressive disorder, or bipolar depression who still have significant symptoms and life impact.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.